AI-generated summary
The authors review transcranial photobiomodulation, a near-infrared light approach to the brain, in animal models of depression and in patients with major depressive disorder. They report that animal and human studies, using varied settings, suggest possible efficacy and good tolerability, and they call for large confirmatory trials.
- Who or what was studied
- Patients with major depressive disorder and animal models of depression
- Limits stated in the abstract
- The abstract describes a narrative review and states that the supporting data call for large confirmatory studies, so evidence certainty is limited.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Transcranial photobiomodulation, Depression, Near-infrared, Cerebral blood flow, Neuromodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.